CKD273 demonstrates benefit of SGLT2 inhibition: link to reducing fibrosis
Nov. 2022
The effect of the sodium–glucose cotransporter 2 (SGLT-2) inhibitor Dapagliflozin was evaluated on the kidney-risk urinary proteomic classifier (CKD273) in persons with type 2 diabetes (T2D) and albuminuria.